SACCHI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.732
EU - Europa 15.039
AS - Asia 13.391
SA - Sud America 1.894
AF - Africa 383
Continente sconosciuto - Info sul continente non disponibili 311
OC - Oceania 38
Totale 66.788
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.930
GB - Regno Unito 6.432
CN - Cina 3.961
SG - Singapore 3.722
IT - Italia 2.538
HK - Hong Kong 1.642
BR - Brasile 1.447
SE - Svezia 1.322
VN - Vietnam 1.306
DE - Germania 1.083
UA - Ucraina 775
FI - Finlandia 667
FR - Francia 607
RU - Federazione Russa 592
BD - Bangladesh 561
TR - Turchia 514
CA - Canada 426
KR - Corea 402
IN - India 292
BG - Bulgaria 263
AR - Argentina 153
MA - Marocco 145
ID - Indonesia 135
JP - Giappone 114
IQ - Iraq 112
NL - Olanda 110
IE - Irlanda 109
PL - Polonia 100
MX - Messico 97
ZA - Sudafrica 83
ES - Italia 77
PK - Pakistan 73
CO - Colombia 68
EC - Ecuador 66
MY - Malesia 62
AE - Emirati Arabi Uniti 58
SA - Arabia Saudita 55
PH - Filippine 53
CZ - Repubblica Ceca 51
CR - Costa Rica 48
BE - Belgio 45
VE - Venezuela 44
CH - Svizzera 43
JM - Giamaica 43
UZ - Uzbekistan 36
CL - Cile 35
LT - Lituania 35
AT - Austria 34
IL - Israele 31
AU - Australia 30
IR - Iran 30
PE - Perù 28
JO - Giordania 26
TW - Taiwan 26
KE - Kenya 25
TT - Trinidad e Tobago 25
AZ - Azerbaigian 24
RO - Romania 24
GT - Guatemala 23
NP - Nepal 23
TN - Tunisia 23
PY - Paraguay 21
NI - Nicaragua 20
EG - Egitto 19
PR - Porto Rico 18
AL - Albania 16
HN - Honduras 16
SC - Seychelles 16
SV - El Salvador 16
TH - Thailandia 16
BH - Bahrain 15
PT - Portogallo 14
BO - Bolivia 13
BZ - Belize 13
DZ - Algeria 13
KZ - Kazakistan 13
UY - Uruguay 13
ET - Etiopia 12
EU - Europa 12
GP - Guadalupe 12
KG - Kirghizistan 12
LB - Libano 12
PA - Panama 12
CW - ???statistics.table.value.countryCode.CW??? 11
DK - Danimarca 11
HU - Ungheria 11
BY - Bielorussia 10
DO - Repubblica Dominicana 10
PS - Palestinian Territory 10
NG - Nigeria 9
NO - Norvegia 9
SN - Senegal 9
EE - Estonia 8
GR - Grecia 8
HR - Croazia 8
NZ - Nuova Zelanda 8
AM - Armenia 7
CY - Cipro 7
OM - Oman 7
SY - Repubblica araba siriana 7
Totale 66.378
Salva come PNG Salva come JPEG
Città #
Ashburn 5.520
Southend 5.360
Santa Clara 2.417
Singapore 2.345
Fairfield 2.102
Hong Kong 1.608
Woodbridge 1.524
Jacksonville 1.503
Chandler 1.444
San Jose 1.359
Houston 1.229
Hefei 1.213
Dearborn 1.033
Ann Arbor 1.031
Council Bluffs 885
Beijing 828
Wilmington 812
Nyköping 756
Seattle 748
Cambridge 699
London 609
Los Angeles 586
New York 461
Ho Chi Minh City 426
Chicago 406
The Dalles 393
Seoul 379
Helsinki 377
Milan 336
Modena 320
Princeton 299
Hanoi 284
San Diego 265
Eugene 261
Sofia 256
Izmir 251
São Paulo 247
Buffalo 232
Lauterbourg 211
Dallas 209
Des Moines 200
Columbus 192
Frankfurt am Main 188
Moscow 168
Rome 145
Toronto 135
Salt Lake City 134
Munich 124
Shanghai 123
Atlanta 112
Casablanca 110
Phoenix 105
Dublin 102
Boardman 91
Falls Church 87
Orem 84
Montreal 81
Jakarta 79
Redwood City 78
Denver 77
San Francisco 76
Warsaw 69
Brooklyn 68
North Bergen 67
Tokyo 67
Elk Grove Village 62
Bremen 60
Guangzhou 59
Da Nang 57
Naples 56
Norwalk 56
Tampa 55
Fremont 51
Miami 48
Nanjing 48
Rio de Janeiro 47
Turku 47
Boston 45
Haiphong 41
Baghdad 40
Brussels 40
Chennai 38
Kunming 37
Philadelphia 37
San José 37
Sterling 37
Miano 36
Turin 36
Belo Horizonte 34
Brno 33
Johannesburg 33
Jinan 32
Bologna 31
Detroit 31
Dhaka 31
Falkenstein 31
Lancaster 31
Brasília 30
Newark 30
Palermo 30
Totale 45.433
Salva come PNG Salva come JPEG
Nome #
Clinical activity and safety of combination immunotherapy with interferon-(2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. 2.964
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 731
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 638
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 573
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 555
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 519
Utilità clinica del dosaggio della beta-tromboglobulina e del fattore piastrinico 4 484
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 480
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 460
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 437
Cinetica piastrinica e indicazione alla splenectomia nella porpora trombocitopenica idiopatica 430
Leucemia eosinofila cronica: descrizione di un caso clinico a lunga sopravvivenza 425
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 423
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 413
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study 412
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 411
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 408
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 400
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 398
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 395
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 394
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 392
Activity of BKM120 and BEZ235 against lymphoma cells 391
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 389
Diagnosis of essential thrombocythemia at platele counts between 400 and 600x10(9)/L. 389
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 376
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 376
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 373
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 368
A concise review of lenalidomide therapy for follicular lymphoma 365
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 361
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 358
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 355
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 352
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 351
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 351
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 351
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 350
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 350
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 349
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 345
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 344
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 339
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 338
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 336
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 334
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 333
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 332
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience 328
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 328
A PROSPECTIVE COMPARISON BETWEEN TREATMENT WITH PHLEBOTOMY ALONE AND WITH INTERFERON-ALPHA IN PATIENTS WITH POLYCYTHEMIA-VERA 325
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 325
Alpha-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Group on ET 319
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 319
Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients. 318
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 315
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 315
Analysis of proliferation activity of myeloid leukaemia cell subsets in ANLL 312
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 312
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 308
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 307
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 307
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. 307
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 306
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 302
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. 301
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4978 301
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 299
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 299
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 299
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 299
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 298
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 298
Alterazione della regione p22-p23 del cromosoma 6 associata a sindrome mieloproliferativa (MPS). 296
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 295
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia 291
Bortezomib and plasma cell leukemia 291
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 288
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 288
Acute nonlymphocytic leukemia with trisomy 4. 287
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 283
Isodicentric X chromosome in myeloproliferative disorders. 283
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 283
Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. 282
The Oral PKC-ß Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. 281
Chromosomes in paroxysmal nocturnal haemoglobinuria. 279
ALPHA-INTERFERON IN THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: CLINICAL RESULTS AND EVALUATION OF ITS BIOLOGICAL EFFECTS ON THE HEMATOPOIETIC NEOPLASTIC CLONE. 278
The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use 275
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors 274
Crisi blastica dopo litioterapia in leucosi mieloide cronica 272
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 272
All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi) 271
Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression 270
Cromosomi marker ed anomalie nucleari nei linfociti di due pazienti con sindrome di Sezary/micosi fungoide. In problemi e prospettive nella medicina moderna. 269
Leucemia e tricoleucociti: studio clinico patologico di 30 casi 268
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 267
Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. 264
Follicular lymphomas: is there a chance for cure? 263
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. 262
Totale 37.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 222.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 222.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.853 0 0 0 0 160 285 188 264 481 280 582 613
2022/20234.224 523 480 272 401 462 745 92 390 510 41 198 110
2023/20242.701 123 154 168 209 617 214 461 275 57 47 108 268
2024/20258.470 328 86 112 616 1.717 1.195 626 412 1.010 429 785 1.154
2025/202619.574 1.064 785 1.423 1.856 2.245 1.293 1.945 923 1.661 1.673 2.241 2.465
2026/20277.424 493 1.258 1.910 3.512 251 0 0 0 0 0 0 0
Totale 66.788